cation: confidential Jeffrey - Biotech forming a base to some extent (strong market backdrop, clearly) you're up S906k on your basket excluding the Ariad (outlier due to m&A prospects vs. group drivers) 1-mo price history charts below. (Embedded image moved to file: pic06061.gif) SGMO lmo Price His

Pharmaceuticals, Inc. Iclusig Comes Back With a New Label and REMS; Upgrade to Outperform and Increase Price Target to $12 On Friday, December 20, Ariad announced that it has reached agreement with the FDA for immediate reauthorization of Iclusig marketing in the United States, with a narrower label

bject: Ariad Attachments: SKMBT_C25313100913160.pdf, Untitled attachment 00458.txt Jeffrey Southern Financial has a position of 16,535 shares of Ariad =harmaceuticals (ARIA)with a cost basis of 17.59 per share. Today the stock is plunging as a result of a cancer drug side effect =see attached). Th